Please select the option that best describes you:

Do you consider MSI testing for mCRPC?  

Based on 2-3% MSH2 mutation and 1% MLH1 mutation rates in metastatic disease regardless of castration sensitivity, should we be looking for this earlier in the disease course (before CRPC) to try to bring PD-1 earlier in therapy?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more